Japan
· Delayed Price · Currency is JPY Astellas Pharma Company Description
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally.
The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution.
The company was founded in 1923 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 1923 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 14,754 |
| CEO | Naoki Okamura |
Contact Details
Address: 2-5-1, Nihonbashi-Honcho Tokyo, 103-8411 Japan | |
| Phone | 81 3 3244 3000 |
| Website | astellas.com |
Stock Details
| Ticker Symbol | 4503 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3942400007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Naoki Okamura | Chief Executive Officer |
| Atsushi Kitamura | Chief Financial Officer |